New drug combo aims to fight back against incurable liver cancer
NCT ID NCT05320692
First seen Jan 05, 2026 · Last updated Apr 19, 2026 · Updated 16 times
Summary
This study is for people with liver cancer that cannot be cured. It is testing if adding two drugs (camrelizumab and rivoceranib) to the standard TACE procedure helps control the cancer better and for longer than using TACE alone. The main goal is to see if this combination can slow the cancer's growth and extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.